Psoriatic Arthritis

Percentage of Newly Diagnosed Patients With Psoriatic Arthritis Starting Biologic DMARDs Who Attained Near Remission or Low Severity Disease Activity (2015-2019)

Percentage of Newly Diagnosed Patients With Psoriatic Arthritis Starting Biologic DMARDs Who Attained Near Remission or Low Severity Disease Activity (N=445)

2015-2019

  1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 Jan;68(1):1-25.

American College of Rheumatology guidelines for psoriatic arthritis recommend a treat-to-target strategy with the target being low disease activity using an established disease activity measure¹. We assessed disease activity using RAPID3, a validated patient-reported composite measure of disease activity. Although RAPID3 was designed for use in rheumatoid arthritis, it has been found useful in many rheumatic diseases including psoriatic arthritis and has been shown to have significant correlation with psoriatic disease activity score. Patients with newly diagnosed psoriatic arthritis started on a biologic DMARD between 2015 and 2019 were reviewed. We considered success as a RAPID3 score of <2.3 (near remission and low severity). 445 psoriatic arthritis patients were started on a biologic DMARD during 2015-2019. Of these, 39.8% achieved a RAPID3 score of <2.3. The percentage of patients in remission or near remission has declined from a high in 2016 of 54.1% to 28.6% in 2019. A significant number of patients remained in moderate or high severity based on RAPID3 scores indicating the need to monitor and apply treat-to-target strategies.